These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39081516)

  • 1. The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies.
    Lu Y; Ao D; He X; Wei X
    MedComm (2020); 2024 Aug; 5(8):e675. PubMed ID: 39081516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?
    Kamble P; Daulatabad V; Singhal A; Ahmed ZS; Choubey A; Bhargava S; John NA
    Horm Mol Biol Clin Investig; 2024 Jun; 45(2):49-53. PubMed ID: 38622986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact.
    Ou G; Yang Y; Zhang S; Niu S; Cai Q; Liu Y; Lu H
    Drug Discov Ther; 2024 Mar; 18(1):67-70. PubMed ID: 38382991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
    Arevalo-Romero JA; Chingaté-López SM; Camacho BA; Alméciga-Díaz CJ; Ramirez-Segura CA
    Heliyon; 2024 Mar; 10(5):e26423. PubMed ID: 38434363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion.
    Li P; Liu Y; Faraone J; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu SL
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appearance and Prevalence of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra.
    Karyakarte RP; Das R; Rajmane MV; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Kulkarni PP; Nizarudeen S; Yanamandra S; Taji N; Joshi S; Potdar V
    Cureus; 2024 Mar; 16(3):e56718. PubMed ID: 38646375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion.
    Li P; Faraone JN; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Xu K; Liu SL
    bioRxiv; 2024 May; ():. PubMed ID: 38826376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia.
    Hamzaoui Z; Ferjani S; Kanzari L; Ben Ali R; Charaa L; Landolsi I; Medini I; Chammam S; Abid S; Ferjani A; Kebaier D; Fakhfakh A; Bouslah Z; Ben Sassi M; Trabelsi S; Boutiba-Ben Boubaker I
    Acta Microbiol Immunol Hung; 2024 Jul; 71(2):165-171. PubMed ID: 38717854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird among Omicron Sublineages.
    Ray SK; Mukherjee S
    Infect Disord Drug Targets; 2025; 25(1):e270624231369. PubMed ID: 38939989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J
    Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39107255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JN.1: enhanced immune evasion ability propels it to become the predominant strain in China, unlikely to trigger pandemic similar to late 2022.
    Du P; Li M; Wei G; Guo C; Li N
    Front Public Health; 2024; 12():1442291. PubMed ID: 39391153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
    Sohail MS; Ahmed SF; Quadeer AA; McKay MR
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.
    Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY
    medRxiv; 2024 Apr; ():. PubMed ID: 38699313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023.
    Jeworowski LM; Mühlemann B; Walper F; Schmidt ML; Jansen J; Krumbholz A; Simon-Lorière E; Jones TC; Corman VM; Drosten C
    Euro Surveill; 2024 Jan; 29(2):. PubMed ID: 38214083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.
    Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY
    Nat Commun; 2024 Oct; 15(1):8550. PubMed ID: 39362845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J
    medRxiv; 2024 Jun; ():. PubMed ID: 38883802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.